Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose

Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose

Mahesh N Samtani,1 Isaac Nuamah,1 Srihari Gopal,1 Bart Remmerie,2 Jennifer Kern Sliwa,3 Larry Alphs31Janssen Research and Development, LLC, NJ, USA; 2Janssen Research and Development, LLC, Division of Janssen Pharmaceutica NV, Beerse, Belgium; 3Janssen Scientific Affairs, LLC, NJ, USABackground: Pal...

Full description

Bibliographic Details
Main Authors:	Samtani MN, Nuamah I, Gopal S, Remmerie B, Sliwa JK, Alphs L
Format:	Article
Language:	English
Published:	Dove Medical Press 2013-05-01
Series:	Neuropsychiatric Disease and Treatment
Online Access:	http://www.dovepress.com/expansion-of-guidance-for-the-day-8-initiation-dose-of-paliperidone-pa-a13096

Similar Items

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
by: Coppola Danielle, et al.
Published: (2012-03-01)

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
by: Coppola, Danielle, et al.
Published: (2012)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
by: Sliwa JK, et al.
Published: (2012-08-01)

Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial
by: Fu Dong-Jing, et al.
Published: (2011-05-01)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
by: Alphs L, et al.
Published: (2013-03-01)

Impact of traditional versus nontraditional initiation dosing schedule of paliperidone palmitate on 30-day readmission and safety
by: Erika Kim, PharmD, BCPP, et al.
Published: (2023-12-01)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
by: Mathews M, et al.
Published: (2019-05-01)

Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies
by: Gopal S, et al.
Published: (2013-09-01)

Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients
by: P. Escobedo-Aedo, et al.
Published: (2022-06-01)

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
by: Mathews M, et al.
Published: (2018-10-01)

A case of tardive dyskinesia with paliperidone palmitate
by: Philip Kumar Boyanapally, et al.
Published: (2015-01-01)

Paliperidone palmitate induced black hairy tongue
by: Bilge Burcak Annagur
Published: (2016-12-01)

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial
by: Ma Yi-Wen, et al.
Published: (2011-04-01)

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
by: Savitz AJ, et al.
Published: (2019-02-01)

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
by: Olivier Corbeil, et al.
Published: (2022-11-01)

Paliperidone palmitate-induced enuresis: a case report
by: S. Cruz, et al.
Published: (2022-06-01)

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
by: Einarson Thomas R, et al.
Published: (2012-07-01)

Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies
by: Srihari Gopal, et al.
Published: (2017-07-01)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
by: O'Donnell A, et al.
Published: (2021-01-01)

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study
by: Si TM, et al.
Published: (2015-06-01)

Alternative initiation regimen of paliperidone palmitate long-acting injectable
by: I.E. Menendez Gil, et al.
Published: (2022-06-01)

Cost-utility analysis of using paliperidone palmitate in schizophrenia in China
by: Rui Luo, et al.
Published: (2023-08-01)

Paliperidone Palmitate-Induced Delirium in an Adolescent with Schizophrenia: Case report
by: Hassan Mirza, et al.
Published: (2018-09-01)

Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults
by: Kim S, et al.
Published: (2012-07-01)

Predictors of transition from paliperidone palmitate 1 and 3 months (PP1M & PPP3M) to paliperidone palmitate 6 months (PP6M)
by: P. J. Escobedo-Aedo, et al.
Published: (2023-03-01)

Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
by: Ibrahim Turkoz, et al.
Published: (2023-09-01)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
by: Charmi Patel, et al.
Published: (2019-11-01)

Alternative initiations with 6-monthly paliperidone palmitate. A descriptive study
by: O. C. Sobrino, et al.
Published: (2023-03-01)

Alternative initiations with 6-monthly paliperidone palmitate. A retrospective study
by: S. Benavente López, et al.
Published: (2023-03-01)

Patient social function and quality of life in schizophrenia: focus on paliperidone palmitate
by: E. V. Grigorieva
Published: (2018-07-01)

Recurrent Priapism Due to Paliperidone Palmitate Use: A Case Report
by: Aydın Kurt
Published: (2022-12-01)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
by: Zhang F, et al.
Published: (2015-03-01)

Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis
by: Li G, et al.
Published: (2021-10-01)

Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
by: Patel, R, et al.
Published: (2017)

Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database
by: Giuseppe Cicala, et al.
Published: (2023-04-01)

In vitro Evaluation of Paliperidone Palmitate Loaded Cubosomes Effective for Nasal-to-Brain Delivery
by: Deruyver L, et al.
Published: (2023-03-01)

Case Report: Paliperidone Palmitate in the Management of Bipolar I Disorder With Non-compliance
by: Kanglai Li, et al.
Published: (2021-01-01)

Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia
by: Juan J. Fernández-Miranda, et al.
Published: (2021-04-01)

Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
by: Taro Kishi, et al.
Published: (2022-12-01)

Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study
by: Giron‐Hernandez C, et al.
Published: (2023-04-01)